While small cap shareholders have become accustomed to major share price gains once a medtech or biotech receives FDA approval to commercialise their products, it’s not all sunshine and rainbows on the FDA horizon as Lumos Diagnostics (ASX: LDX) has found, following the rejection of their FebriDx test kits. As a rapid diagnostic test that
Read MoreThe rapidly evolving marketplace around a vaccine for COVID-19 and ongoing management has taken another turn in the right direction with biotech company AnteoTech (ASX: ADO) readying for clinical trials of their Antigen Rapid Test (ART) which can be done using just a person’s saliva sample. The ART is another medical advancement in the market
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.